Does hyperinsulinemia reduce hepatic SHBG and raise free testosterone exposure?

Sex hormone-binding globulin (SHBG) is a glycoprotein produced by the liver that serves as the primary regulator of androgen bioavailability. The relationship between elevated insulin and suppressed SHBG is a foundational mechanism in metabolic and endocrine disorders, particularly impacting hormonal balance in women.

Clinical and mechanistic evidence

The suppression of SHBG by insulin is a well-documented physiological process, supported by both laboratory models and clinical observation:

• Direct Hepatic Suppression: Insulin acts as a potent inhibitor of SHBG synthesis within the liver. Evidence from human hepatoma cell lines (HepG2) shows that insulin reduces SHBG mRNA levels and protein secretion in a dose-dependent manner.
• Transcriptional Control: Mechanistically, hyperinsulinemia downregulates the expression of HNF-4α (hepatocyte nuclear factor-4 alpha), a critical transcription factor required for the SHBG gene promoter. Additionally, insulin increases levels of SREBP-1c, which further suppresses HNF-4α activity.
• In Vivo Confirmation: Hyperinsulinemic-euglycemic clamp studies demonstrate that acute elevations in insulin significantly lower circulating SHBG concentrations. This effect occurs independently of sex steroid levels, confirming insulin as a primary regulator.

Hormonal and tissue exposure

SHBG binds testosterone with high affinity, effectively sequestering it from tissues. When SHBG levels drop due to hyperinsulinemia, the distribution of testosterone shifts:

• Increased Bioavailability: Total testosterone is divided into SHBG-bound, albumin-bound, and free fractions. Because SHBG-bound testosterone is biologically inactive, a reduction in SHBG directly increases the "free" and "bioavailable" fractions—the portions capable of entering cells and activating androgen receptors.
• Clinical Implications: In populations such as women with Polycystic Ovary Syndrome (PCOS), there is a strong inverse correlation between fasting insulin and SHBG. Clinical data show that lowering insulin (via weight loss or metformin) successfully raises SHBG levels, which subsequently reduces free testosterone exposure.

Bottom line

Hyperinsulinemia directly suppresses hepatic SHBG production by inhibiting the HNF-4α transcriptional pathway. This reduction in SHBG increases the fraction of free, biologically active testosterone, leading to higher systemic androgen exposure even if total testosterone levels remain constant.